However, the drug combination upregulated the expression of p21 and p27 proteins and downregulated cyclin D1 in four sensitive lymphoid cell lines: WSU-NHL, RL, Karpas-422, and L-540 (Fig. 4a). The gene discussed is CCND1; the disease is non-Hodgkin lymphoma.